Study #2022-0439
P-RAD: A randomized study of preoperative chemotherapy, pembrolizumab and No, low or high dose radiation in node-positive, HER2-negative breast cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
Pembrolizumab, Paclitaxel, Carboplatin, Cyclophosphamide, Doxorubicin, Capecitabine
Description
This research trial is studying a combination of neoadjuvant radiotherapy (RT), immunotherapy (pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone receptor positive/HER2-negative breast cancer. The names of the study interventions involved in this study are: * Radiation Therapy (RT) * Immunotherapy: Pembrolizumab (MK-3475) * Chemotherapies: * Paclitaxel * Doxorubicin (also called Adriamycin) * Cyclophosphamide * Carboplatin (optional, and in TN only) * Capecitabine (optional, and in TN only)
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
Study phase:
Phase II
Physician name:
Haven Garber
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-833-992-0260
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.